ISSN |
1948-9358 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Endocrinology & Metabolism |
Manuscript Type |
Basic Study |
Article Title |
Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Vadim V Klimontov, Anton I Korbut, Iuliia S Taskaeva, Nataliya P Bgatova, Maksim V Dashkin, Nikolay B Orlov, Anna S Khotskina, Evgenii L Zavyalov and Thomas Klein |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
the Ministry of Education and Science of Russia |
АААА-А19-119031590017-7/0324-2019-0045-C-02 |
Boehringer Ingelheim Pharma |
|
|
Corresponding Author |
Vadim V Klimontov, DSc, MD, PhD, Professor, Department of Laboratory of Endocrinology, Research Institute of Clinical and Experimental Lymphology–Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (RICEL–Branch of IC&G SB RAS), No. 2 Timakov Street, Novosibirsk 630060, Russia. klimontov@mail.ru |
Key Words |
Diabetes; Chronic kidney disease; Albuminuria; Podocyte; Sodium-glucose transporter 2 inhibitors; Empagliflozin |
Core Tip |
In our study, we assessed the influence of sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin (EMPA) on glomerular structure, with special interest to podocytes, and glomerular staining of nephrin in db/db mice, a model of type 2 diabetic nephropathy. We treated 8-wk-old mice with EMPA (10 mg per kg daily) or vehicle for 8 wks. The results demonstrated that EMPA attenuates podocytopathy and enhances glomerular nephrin staining. These effects were accompanied by mitigation of renal hypertrophy and glomerular transforming growth factor beta expression and decrease in albuminuria. The results contribute to understanding renal protective effect of SGLT2 inhibitors in diabetes. |
Publish Date |
2020-12-13 05:45 |
Citation |
Klimontov VV, Korbut AI, Taskaeva IS, Bgatova NP, Dashkin MV, Orlov NB, Khotskina AS, Zavyalov EL, Klein T. Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice. World J Diabetes 2020; 11(12): 596-610 |
URL |
https://www.wjgnet.com/1948-9358/full/v11/i12/596.htm |
DOI |
https://dx.doi.org/10.4239/wjd.v11.i12.596 |